Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01621178 · ClinicalTrials.gov registry record · Phase 3
A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 577
- Enrollment target
NCT01621178 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 577 participants.
The verdict
NCT01621178, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 577 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the glycemic efficacy and safety of dulaglutide compared to insulin glargine in the treatment of participants with type 2 diabetes and moderate or severe chronic kidney disease.
Interventions
- DRUG Insulin glargine
- DRUG Dulaglutide
- DRUG Insulin lispro
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 577 participants |
| Start Date | 2012-07 |
| Est. Completion | 2016-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01621178
The ClinicalTrials.gov registry entry for NCT01621178 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 577 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Insulin glargine is the first listed.
NCT01621178 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01621178 about?
NCT01621178 is a clinical study titled "A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)". The purpose of this study is to determine the glycemic efficacy and safety of dulaglutide compared to insulin glargine in the treatment of participants with type 2 diabetes and moderate or severe chronic kidney disease.
What is the current status of trial NCT01621178?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 577 participants. The study started on 2012-07. Estimated completion is 2016-12.
What interventions are being tested in trial NCT01621178?
The interventions under investigation include: Insulin glargine (DRUG), Dulaglutide (DRUG), Insulin lispro (DRUG).
Who is sponsoring clinical trial NCT01621178?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.